Table 1.
Author | Age | Sex | Chemotherapy | Status |
---|---|---|---|---|
Kalra et al. [2] | 21 | F | Vinblastine, bleomycin, and cisplatin | Died during treatment |
| ||||
Tuy et al. [3] | 37 | F | None | Died from disease progression |
| ||||
Boss et al. [4] | 57 | F | Doxorubicin and cisplatin; ifosfamide and etoposide; Cyclophosphamide and imatinib; E7080 | Initial success with E7080, followed by disease progression |
| ||||
Masrouha et al. [5] | 17 | F | Regimen unknown | Lung metastases |
14 | M | Regimen unknown | Died during treatment | |
17 | F | Regimen unknown | No recurrence | |
17 | M | Regimen unknown | Lung metastases | |
5 | M | Regimen unknown | Died during treatment | |
| ||||
Leidinger et al. [6] | 18 | F | COSS-96; COSS-96 with carboplatin, etoposide, and RT | Lost to follow-up |
| ||||
Oshrine et al. [7] | 14 | F | Doxorubicin and ifosfamide, cisplatin regimen | Disease free after 6 months |
| ||||
Ordonez et al. [8] | 26 | F | Unknown | Unknown |
| ||||
Our case | 26 | F | Methotrexate and ifosfamide | Died from progressive disease |